English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the zaia usage as premium feature

ZAIA

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the access of premium content as premium feature

Premium Content

Zendy Tools

Zendy Open

(-)-Epigallocatechin-3-gallate (EGCG) in combination with the catechol-O-methyltransferase (COMT) inhibitors, entacapone or tolcapone, synergistically reduced the viability of lung cancer cells. This inhibition corresponded to increased cellular bioavailability of unmethylated EGCG, increased intracellular oxidative stress, and inhibition of cell cycle progression.

carcinogenesis

Synergistic inhibition of lung cancer cell lines by (−)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-              O              -methyltransferase